Download PDF
CC BY-NC-ND 4.0 · Arq Neuropsiquiatr 2017; 75(02): 87-91
DOI: 10.1590/0004-282X20160191
ARTICLES

Treatment of hemifacial spasm with botulinum toxin type a: effective, long lasting and well tolerated

Tratamento do espasmo hemi-facial com toxina botulínica tipo a foi efetivo, bem tolerado e com efeito sustentado
Jean Pierre Mette Batisti
1   Universidade Federal do Paraná, Hospital de Clínicas, Curitiba PR, Brasil;
,
Alais Daiane Fadini Kleinfelder
1   Universidade Federal do Paraná, Hospital de Clínicas, Curitiba PR, Brasil;
,
Natália Bassalobre Galli
1   Universidade Federal do Paraná, Hospital de Clínicas, Curitiba PR, Brasil;
,
Adriana Moro
2   Universidade Federal do Paraná, Hospital de Clínicas, Unidade de Distúrbios do Movimento, Departamento de Medicina Interna, Serviço de Neurologia, Curitiba PR, Brasil;
,
Renato Puppi Munhoz
3   University Health Network, Morton and Gloria Shulman Movement Disorders Centre and the Edmond J. Safra Program in Parkinson’s Disease, Toronto Western Hospital, Toronto, Ontario, Canada.
,
Hélio Afonso Ghizoni Teive
2   Universidade Federal do Paraná, Hospital de Clínicas, Unidade de Distúrbios do Movimento, Departamento de Medicina Interna, Serviço de Neurologia, Curitiba PR, Brasil;
› Author Affiliations
› Further Information
Also available at
   Permissions and Reprints

ABSTRACT

Hemifacial spasm (HFS) is a common movement disorder characterized by involuntary tonic or clonic contractions of the muscles innervated by the facial nerve.

Objective

To evaluate the long-term effect of botulinum toxin type A (BTX-A) in the treatment of HFS.

Methods

A retrospective analysis of patients treated at the Movement Disorders Outpatient Clinic in the Neurology Service, Hospital de Clínicas, Federal University of Paraná, Curitiba, from 2009 to 2013 was carried out. A total of 550 BTX-A injections were administered to 100 HFS patients.

Results

Mean duration of improvement following each injection session was 3.1 months, mean latency to detection of improvement was 7.1 days and mean success rate was 94.7%. Patients were evaluated at an interval of 5.8 months after each application. Adverse effects, which were mostly minor, were observed in 37% of the patients at least once during follow-up. The most frequent was ptosis (35.1%).

Conclusion

Treatment of HFS with BTX-A was effective, sustainable and safe and had minimal, well-tolerated side effects.

RESUMO

O espasmo hemifacial (EHF) é um distúrbio do movimento comum, caracterizado pela presença de contrações musculares tçnicas ou clçnicas dos músculos inervados pelo nervo facial.

Objetivo

Avaliar o efeito em longo prazo do uso da toxina botulínica tipo A (TXB) no tratamento do espasmo hemifacial (EHF).

Métodos

Foi realizada uma análise retrospectiva de pacientes do Ambulatório de Distúrbios do Movimento do departamento de Neurologia do Hospital das Clínicas da Universidade Federal do Paraná entre 2009 e 2013. Foram administradas 550 doses em 100 portadores de EHF.

Resultados

A duração média de efeito foi de 3,14 meses, com latência de 7,10 dias e a taxa de sucesso foi de 94,73%. Os pacientes foram reavaliados pelo médico em um intervalo de 5,76 meses após cada aplicação. Efeitos adversos transitórios, em sua maioria menores, foram observados em 37% dos pacientes ao menos uma vez durante o seguimento e o mais freqüente foi ptose palpebral (35,14%).

Conclusão

O tratamento do EHF com TXB-A mostrou-se eficaz, sustentado e seguro, com efeitos colaterais mínimos e bem tolerados.

botulinum toxins - botulinum toxin type A - hemifacial spasm
toxinas botulínicas - toxina botulínica tipo A - espasmo hemifacial


Publication History

Received: 12 March 2016

Accepted: 18 October 2016

Article published online:
05 September 2023

© 2023. Academia Brasileira de Neurologia. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commecial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Revinter Publicações Ltda.
Rua do Matoso 170, Rio de Janeiro, RJ, CEP 20270-135, Brazil

 

  • References

  • 1 Abbruzzese G, Berardelli A, Defazio G. Hemifacial spasm. Handb Clin Neurol. 2011;100:675-80. http://doi.org/10.1016/B978-0-444-52014-2.00048-3
  • 2 Sorgun MH, Yilmaz R, Akin YA, Mercan FN, Akbostanci MC. Botulinum toxin injections for the treatment of hemifacial spasm over 16 years. J Clin Neurosci. 2015;22(8):1319-25. http://doi.org/10.1016/j.jocn.2015.02.032.
  • 3 Yaltho TC, Jankovic J. The many faces of hemifacial spasm: differential diagnosis of unilateral facial spasms. Mov Disord. 2011;26(9):1582-92. http://doi.org/10.1002/mds.23692
  • 4 Norton J. Is hemifacial spasm of peripheral or central origin? Can J Neurol Sci. 2014;41(2):142. http://doi.org/10.1017/S0317167100016498
  • 5 Wilkinson MF, Kaufmann AM. Facial motor neuron excitability in hemifacial spasm: a facial MEP study. Can J Neurol Sci. 2014;41(2):239-45. http://doi.org/10.1017/S0317167100016644
  • 6 Munhoz RP, Teive HA, Della Coletta MV, Germiniani FM, Iwamoto FM, Camargo CH et al. Frequency of obsessive and compulsive symptoms in patients with blepharospasm and hemifacial spasm. Arq Neuropsiquiatr. 2005;63(2A):213-6. http://doi.org/10.1590/S0004-282X2005000200004
  • 7 Rosenstengel C, Matthes M, Baldauf J, Fleck S, Schroeder H. Hemifacial spasm: conservative and surgical treatment options. Dtsch Arztebl Int.. 2012;109(41):667-73. http://doi.org/10.3238/arztebl.2012.0667
  • 8 Wang A, Jankovic J. Hemifacial spasm: clinical findings and treatment. Muscle Nerve. 1998;21(12):740-7. http://doi.org/10.1002/(SICI)1097-4598(199812)21:12<1740::AID-MUS17>3.0.CO;2-V
  • 9 Park HL, Lim SM, Kim TH, Kang KH, Kang H, Jung YH et al. Intractable hemifacial spasm treated by pulsed radiofrequency treatment. Korean J Pain. 2013;26(1):62-4. http://doi.org/10.3344/kjp.2013.26.1.62
  • 10 Singh S. Botulinum toxin in hemifacial spasm: revisited. Indian J Plast Surg. 2013;46(1):159-60. http://doi.org/10.4103/0970-0358.113746
  • 11 Mezaki T. [Clinical application of botulinum toxin]. Brain Nerve. 2011;63(7):785-94. Japanese.
  • 12 Hallett M, Albanese A, Dressler D, Segal KR, Simpson DM, Truong D et al. Evidence-based review and assessment of botulinum neurotoxin for the treatment of movement disorders. Toxicon. 2013;67:94-114. http://doi.org/10.1016/j.toxicon.2012.12.004
  • 13 Xu YP, Shen J, Zhu QB, Gu J, Lin SZ, Fan JP. Efficacy of botulinum toxin A for treatment of unilateral spasms of the eyelid and its prognosis. Eur Rev Med Pharmacol Sci. 2013;17(21):2974-9.
  • 14 Brin MF. Botulinum toxin: chemistry, pharmacology, toxicity and immunology. Muscle Nerve Suppl. 1997;6:S146-68.
  • 15 Ministério da Saúde (BR). Portaria Nº 376, de 13 de abril de 2016. Habilita o Hospital da Mulher como unidade de assistência de alta complexidade em neurocirurgia. Diário Oficial União. 15 abr 2016;seção 1:39.
  • 16 Felicio AC, Godeiro Junior CO, Borges V, Silva S, Ferraz HB. Clinical assessment of patients with primary and postparalytic hemifacial spasm: a retrospective study. Arq Neuropsiquiatr. 2007;65(3B):783-6. http://doi.org/10.1590/S0004-282X2007000500009
  • 17 Barbosa ER, Takada LT, Gonçalves LR, Costa RM, Silveira-Moriyama L, Chien HF. Botulinum toxin type A in the treatment of hemifacial spasm: an 11-year experience. Arq Neuropsiquiatr. 2010;68(4):502-5. http://doi.org/10.1590/S0004-282X2010000400006
  • 18 Thussu A, Barman C, Prabhakar S. Botulinum toxin treatment of hemifacial spasm and blepharospasm : objective response evaluation. Neurol India. 1999;47(3):206-9.
  • 19 Bares M, Streitova H. Long-term therapy of benign essential blepharospasm and facial hemispasm with botulinum toxin A : retrospective assessment of the clinical and quality of life impact in patients treated for more than 15 years. Acta Neurol Belg. 2014;45:1-7. http://doi.org/10.1007/s13760-014-0285-z
  • 20 Wu CJ, Shen JH, Chen Y, Lian YJ. Comparison of two different formulations of botulinum toxin a for the treatment of blepharospasm and hemifacial spasm. Turkish Neurosurg. 2011;21(4):625-9.
  • 21 Rieder CRM, Schestatsky P, Socal, MP, Monte TL, Fricke D, Costa J. A double-blind, randomized, crossover study of prosigne versus botox in patients with blepharospasm and hemifacial spasm. Clin Neuropharmacol. 2007;30(1) 39-42. http://doi.org/10.1097/01.WNF.0000236771.77021.3C
  • 22 Quagliato EM, Carelli EF, Viana MA. Prospective, randomized, double-blind study, comparing botulinum toxins type a botox and prosigne for blepharospasm and hemifacial spasm treatment. Clin Neuropharmacol .2010;33(1):27-31. http://doi.org/10.1097/WNF.0b013e3181c46f61
  • 23 Cannon PS, MacKenzie KR, Cook AE, Leatherbarrow B. Difference in response to botulinum toxin type A treatment between patients with benign essential blepharospasm and hemifacial spasm. Clin Experiment Ophthalmol. 2010;38(7):688-91. http://doi.org/10.1111/j.1442-9071.2010.02303.x
  • 24 Cillino S, Raimondi G, Guépratte N, Damiani S, Cillino M, Di Pace F, Casuccio A. Long-term efficacy of botulinum toxin A for treatment of blepharospasm, hemifacial spasm, and spastic entropion: a multicentre study using two drug-dose escalation indexes. Eye (Lond). 2010;24(4):600-7. http://doi.org/10.1038/eye.2009.192
  • 25 Defazio G, Berardelli A, Abbruzzese G, Coviello V, De Salvia R, Federico F et al. Primary hemifacial spasm and arterial hypertension: a multicenter case-control study. Neurology. 2000;54(5):1198-200. http://doi.org/10.1212/WNL.54.5.1198
  • 26 Schellini SA, Matai O, Igami TZ, Padovani CR, Padovani CP. [Essential blepharospasm and hemifacial spasm: characteristic of the patient, botulinum toxin a treatment and literature review]. Arq Bras Oftalmol. 2006;69(1):23-6. Portuguese. http://doi.org/10.1590/S0004-27492006000100005
  • 27 Kollewe K, Mohammadi B, Dengler R, Dressler D. Hemifacial spasm and reinnervation synkinesias: long-term treatment with either Botox or Dysport. J Neural Transm (Vienna). 2010;117(6):795-63. http://doi.org/10.1007/s00702-010-0409-4
  • 28 Wang L, Hu X, Dong H, Wang W, Huang Y, Jin L et al. Clinical features and treatment status of hemifacial spasm in China. Chin Med J (Engl). 2014;127(5):845-9.
  • 29 Czyz CN, Burns JA, Petrie TP, Watkins JR, Cahill KV, Foster JA. Long-term botulinum toxin treatment of benign essential blepharospasm, hemifacial spasm, and Meige syndrome. Am J Ophthalmol. 2013;156(1):173-7.e2. http://doi.org/10.1016/j.ajo.2013.02.001
  • 30 Mejia NI, Vuong KD, Jankovic J. Long-term botulinum toxin efficacy, safety, and immunogenicity. Mov Disord. 2005;20(5):592-7. http://doi.org/10.1002/mds.20376